Tuesday 11 November 2014

Sanofi's dual-action biotech asthma drug performs well in test

(Reuters) - An experimental biotech drug for moderate to severe asthma from France's Sanofi and its U.S. partner Regeneron has produced good results in clinical tests, suggesting that its dual-action mechanism may be highly effective.


via Reuters: Health News Read More Here..

No comments:

Post a Comment